Results 81 to 90 of about 85,335 (283)
Tacrolimus-Associated Dilated Cardiomyopathy in Adult Patient After Orthotopic Liver Transplant
This report presents a case of tacrolimus cardiotoxicity in an adult patient who received tacrolimus immunosuppression for orthotopic liver transplant (OLT).
Jennifer McLeod MD +3 more
doaj +1 more source
Central nervous system (CNS) neurons fail to regrow injured axons, often resulting in permanently lost neurologic function. Tacrolimus is an FDA-approved immunosuppressive drug with known neuroprotective and neuroregenerative properties in the CNS ...
Yolandi van der Merwe +12 more
doaj +1 more source
Tacrolimus ointment in the management of atopic dermatitis
Antonello Baldo, Mariana Cafiero, Paola Di Caterino, Luisa Di CostanzoDepartment of Dermatology, University of Naples Federico II, Naples, ItalyAbstract: Atopic dermatitis (AD) is a chronic, relapsing, highly pruritic inflammatory skin disease.
Paola Di Caterino +3 more
core
The extent of pharmacogenetic (PGx) drug dispensing among Dutch adults receiving medications for cardiovascular disease (CVD) is unknown. Using the University of Groningen IADB.nl pharmacy database, we performed a serial cross‐sectional study (2019–2023) to estimate the annual prevalence of PGx drug dispensing and annual rates of initiation.
Zhuolin Zhang +5 more
wiley +1 more source
Topical tacrolimus : efficacy and tolerability
Tacrolimus, formulated as a 0.1% or 0.03% ointment, is the first topical immunosuppressant to receive widespread regulatory approval. Currently, it is only approved for the second-line treatment of moderate or severe atopic eczema in adults and children >
Lee, Frederick J. +1 more
core
Modifying Tacrolimus-related Toxicity After Liver Transplantation Comparing Life Cycle Pharma Tacrolimus Versus Extended-released Tacrolimus: A Multicenter, Randomized Controlled Trial [PDF]
Background:The aim of this open-label, multicenter, randomized controlled study was to investigate whether the life cycle pharma (LCP)-tacrolimus compared with the extended-release (ER)-tacrolimus formulation results in a difference in the prevalence of ...
de Winter, Brenda C.M.; id_orcid +41 more
core +2 more sources
BackgroundVarious preparations of tacrolimus have been implemented for patients with vernal keratoconjunctivitis (VKC). However, there is a lack of evidence regarding the safety and effectiveness of different dosages and forms of tacrolimus for patients ...
Reem AlHuthail
doaj +1 more source
Overview of extended release tacrolimus in solid organ transplantation. [PDF]
Tacrolimus (Prograf(©), Astellas Pharma Europe Ltd, Staines, United Kingdom; referred to as tacrolimus-BID) is an immunosuppressive agent to prevent and treat allograft rejection in kidney transplant recipients in combination with mycophenolate mofetil ...
Joshua Rusinak (12544975) +5 more
core +1 more source
P Dalal1, G Shah1, D Chhabra2, Lorenzo Gallon21Department of Medicine, Mount Sinai Hospital, Chicago; 2Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USAIntroduction: Several new medications are now available for ...
P Dalal, D Chhabra, G Shah, et al
core

